Fresenius Kabi launches Acetylcysteine Solution 10% in multiple doses

So far, Acetylcysteine Solution, USP vial for inhalation (mucolytic agent) or oral administration has been on the drug-shortage lists maintained by both the US Food and Drug Administration (FDA) and the American Society of Health-System Pharmacists.

With the launch of Acetylcysteine Solution, USP, 10%, the company now provides the largest portfolio of Acetylcysteine Solution products.

The German health care firm also provides an Acetylcysteine 20% portfolio comprising 4mL, 10mL and 30mL vials.

Fresenius Kabi USA president and CEO John Ducker said since 2008, the company has responded multiple times and in a variety of ways to meet clinician and patient needs due to US drug shortages.

"The introduction of Acetylcysteine 10% is another example of our commitment to provide needed products in convenient presentations," Ducker said.

Acetylcysteine for inhalation is used as adjuvant therapy for patients with certain lung diseases including chronic and acute bronchopulmonary disease.